Recommended if funds allow
Statement of Benefit to California:
SYNOPSIS: The investigator proposes to utilize gene modification protocols to engineer human embryonic stem cells that, upon hematopoietic differentiation, generate macrophages and T-lymphocytes that are resistant to HIV infection. He proposes to use methodologies and vectors already developed and tested in hematopoietic stem cells in the human embryonic stem cell system. The proposal is focused on down-regulation of CCR5 using siRNA methodology in T-cells and macrophages, or ablating its expression by homologous recombination mediated by zinc finger nucleases. In addition, if time allows, similar experiments will be performed in an effort to down-regulate TRIM 5-alpha. CCR5 serves as a co-receptor for HIV entry of R5 tropic HIV strain. Rhesus TRIM5-alpha renders cells resistant to HIV-1 infection. Data are available indicating that a single amino acid substitution will convert human TRIM5-alpha to a form that renders cells resistant to HIV infection. SIGNIFICANCE AND INNOVATION: This is an excellent application of hESC biology to HIV disease by a productive, innovative investigator. The line of investigation is new and timely. The PI proposes to determine if an important HIV receptor can be down-regulated or knocked-out entirely in hES cells, thus producing cell lines resistant to HIV infection. Such cell lines could then be differentiated into mature macrophages and T-lymphocytes for therapeutic purposes. The investigator proposes state-of-the-art gene transfer methodology and, through his collaboration with Dr. Zack, he will utilize state-of-the-art methodology for deriving mature hematopoietic cells from human embryonic stem cells. The approaches have been well tested in the hematopoietic system and in cultured cell lines, and therefore appear quite feasible. As appropriately emphasized by the investigator, HIV infection remains a significant problem and genetic engineering strategies to create resistant cells in infected individuals are highly desirable. The ability to expand genetically modified cells and obtain subclones offers the theoretical advantage of providing therapy with a "safer" stem cell population although the practicality of this approach and its true advantages remain to be established. STRENGTHS: The PI is highly experienced and uniquely well-suited for this line of investigation, which would answer some important questions about both hES cell responses to genetic manipulation and the utility of genetically manipulated cells in treating a global infectious disease. Establishing the methodology for this work, including the lentiviral vector-mediated gene transfer and the use of siRNA to modulate CCR5 expression, is important. Their collaborator also has made significant progress in obtaining hematopoietic differentiation from human embryonic stem cells. WEAKNESSES: To some extent the proposal lacks innovation since it simply outlines experiments already performed with hematopoietic stem cells utilizing the more complex embryonic stem cell system. The ability to achieve zinc finger nuclease mediated homologous recombination in human embryonic stem cells remains to be established. There is also concern that enforced expression of nucleases may non-specifically damage the genome with mutagenic potential. Importantly, the differences between mES cells and hES cells in culture may not be fully appreciated by this investigative team. DISCUSSION: This proposal presents a mixture of extending what this group appears to be doing already and adding the new element of homologous recombination. The methodology is state-of-the-art, and the PI is a senior AIDS researcher who is uniquely qualified to do the work; however there is a question of whether it is worthwhile to redo these experiments in hESCs. How applicable will hESC be to HIV studies? Reviewer felt that perhaps it might be useful work to make the cells. Regarding Specific Aim 2, one suggestion is that the PI could first screen clones for productive homologous recombination events using replicative potential in-vitro, and then look for those integration events that are non-harmful (i.e., non-leukemic).